Last reviewed · How we verify
VS-6063
At a glance
| Generic name | VS-6063 |
|---|---|
| Also known as | defactinib |
| Sponsor | Verastem, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (PHASE2)
- A Study of Avutometinib and Defactinib in People With Thyroid Cancer (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma (PHASE2)
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma (PHASE2)
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (PHASE1)
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (PHASE3)
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VS-6063 CI brief — competitive landscape report
- VS-6063 updates RSS · CI watch RSS
- Verastem, Inc. portfolio CI